[Edaily Reporter Kim Hyung-il ] TONGYANG PILE, Inc.(228340), a company specializing in concrete piles for foundation reinforcement, hit the daily price limit as it gained attention as a stock related to disaster safety and earthquake-resistant infrastructure.
TONGYANG PILE, Inc. CI. (Photo: TONGYANG PILE, Inc.)
According to MP Doctor on the 2nd, as of 10:28 a.m., TONGYANG PILE, Inc. was trading at 3,885 won, up 895 won (29.93%) from the previous trading day. The stock reached the daily price limit around 10:10 a.m. and has remained there since.
No specific announcements regarding TONGYANG PILE, Inc. were made today. This is interpreted as buying interest flowing into infrastructure companies—such as those specializing in earthquake-resistant materials and ground reinforcement—amid growing public concern over disaster prevention and building safety.
TONGYANG PILE, Inc. is a construction materials company whose core business is the manufacture and sale of concrete piles. Its main product, high-strength concrete piles (PHC), is used to reinforce the ground and support structures during foundation work for buildings. Market analysts are also pointing to the potential for the company to benefit from expanded investment in earthquake-resistant design and ground reinforcement infrastructure.
Earnings have also improved. TONGYANG PILE, Inc.’s second-quarter revenue this year reached approximately 20.676 billion won, an increase from the previous quarter, and the company posted a profit with an operating profit of 2.344 billion won and a net income of 2.43 billion won.
SamsungElectronics will showcase its “AI Living” experience—which connects TVs, home appliances, and mobile devices to support everything from leisure and household chores to health management—at “IFA…
MetaImmuneTech, a company specializing in digital immune cell analysis platforms, has partnered with Vaxcell-Bio Therapeutics(323990), a developer of anti-cancer immunotherapies, to begin actively pio…
Inventage Lab Inc.(389470)The company has begun technical validation of its next-generation subcutaneous (SC) formulation modification platform, “IVL-BioFluidic™.” It has signed Material Transfer Agre…